Adverse events

Most adverse events associated with NuvaRing use are common to other forms of hormonal contraceptives, including headache and breast tenderness.1,3

Hormone-related side effects occurring with NuvaRing and a COC containing 30 μg ethinylestradiol and 3 mg of drospirenone. Adapted from Ahrendt et al.3

NuvaRing provides low, steady-state, continuous dosing

Device-related adverse events include medical device discomfort, expulsion of the device from the vagina, and less commonly, contraceptive device complication and device breakage.1

As with other hormonal contraceptives, there are warnings for use and interactions with other medicinal products, which may lead to breakthrough bleeding or contraceptive failure.1 For a full list of undesirable effects and adverse events that may be associated with NuvaRing use, please refer to the Summary of Product Characteristics.

 

 

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to MSD Drug Safety Department on 01707 363773

Organon

Expiry 10/11 - NUV.10.GB.27040.AV

© 2010 Copyright Organon Laboratories Limited. All rights reserved.

Terms and Conditions
Privacy Policy


© 2010 Organon Laboratories Ltd trading as MSD: Registered Address: Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU.
A company registered in England and Wales. Company Registration Number: 820771